Navigation Links
BioLineRx Presents Positive Preclinical Results of Acute Myeloid Leukemia Treatment at ASH Conference
Date:12/10/2013

JERUSALEM, Dec. 10, 2013 /PRNewswire/ -- BioLineRx (NASDAQ: BLRX; TASE: BLRX), a biopharmaceutical development company, announced today that positive preclinical results of BL-8040 (formerly known as BKT-140), for the treatment of Acute Myeloid Leukemia (AML) and other hematological indications, have been presented as a poster at the 55th Annual Meeting of the American Society of Hematology (ASH). The data show that BL-8040 is efficient in inducing the death of AML cancer cells both in vitro and in a humanized mouse model.

(Logo: http://photos.prnewswire.com/prnh/20130730/630769)

BL-8040 is a novel, potent and selective inhibitor of the CXCR4 chemokine receptor, which is normally activated by the chemokine ligand CXCL12. Both CXCL12 and its receptor, CXCR4, are key players in enabling AML cancer cells to hide and thrive in the bone marrow, and CXCR4 expression in AML patients is associated with poor prognosis. FLT3 mutations are detected in approximately 30% of AML cases and are associated with poor prognosis and a high incidence of relapse in AML patients. In addition, expression of the CXCR4 receptor in FLT3 mutated AML is also correlated with poor outcomes. Accordingly, it is believed that inhibition of CXCR4 may sensitize AML cells toward chemotherapy and FLT-3 targeted therapies.

The data presented in the conference show that BL-8040 directly inhibits AML cell growth and induces cell death, both in cell cultures and in mice engrafted with human AML cells. In addition, the ability of BL-8040 to induce mobilization of AML cells from the bone marrow into the blood circulation enhanced the chemotherapeutic effect of ARA-C (one of the standard-of-care chemotherapies for AML). The effects were even more robust in cells harboring the FLT3 mutation and a synergistic
'/>"/>

SOURCE BioLineRx
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. BioLineRx Announces Publication of Positive Pre-Clinical Results for BL-8040 in Treatment of Thrombocytopenia
2. BioLineRx Reports Second Quarter 2013 Results
3. BioLineRx Appoints B. J. Bormann to Board of Directors
4. BioLineRx to Present at 2013 Stifel Nicolaus Healthcare Conference In Boston
5. BioLineRx to Present at 15th International Celiac Disease Symposium
6. BioLineRx Announces Issuance of United States Patent Covering Use of BL-8040 for Obtaining Stem Cells
7. BioLineRx To Present At 15th Annual Rodman & Renshaw Global Investment Conference In New York
8. BioLineRx Announces Receipt of a Notice of Allowance from USPTO for Patent on Use of BL-8020, an Oral, Interferon-Free Treatment for Hepatitis C
9. BioLineRx Announces Regulatory Submission for Phase 1/2 Trial for Novel Treatment of Celiac Disease
10. BioLineRx Announces In-Licensing of BL-9020, for Treatment of Type 1 Diabetes
11. BioLineRx Receives Regulatory Approval to Commence Phase 1/2 Trial for Novel Treatment of Celiac Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced that ... investor conferences.  , 31 st NASDAQ Investor ... 2, 2014 at 6:45 a.m. EST / 11:45 a.m. GMT. ... will provide an overview of the company and a business and ... Conference in New York, NY on Tuesday, ...
(Date:11/26/2014)... 26, 2014 / -- China Nepstar Chain Drugstore Ltd. (NYSE: ... drugstore chain in China based ... the appointment of Ms. Rebecca Yingnan Zhang ... Ms.Zhang has over 20 years of experience ... 1999. Prior to Ms. Zhang,s appointment as the Company,s ...
(Date:11/24/2014)... DIEGO , Nov. 24, 2014  Arena Pharmaceuticals, Inc. ... scheduled to present a corporate overview and update at the ... December 2, 2014, at 8:30 a.m. Eastern Time (5:30 a.m. ... New York . A live audio ... relations section of Arena,s website at www.arenapharm.com . A ...
Breaking Medicine Technology:Jazz Pharmaceuticals Announces Participation in Two Investor Conferences 2China Nepstar Chain Drugstore Appoints Ms. Rebecca Yingnan Zhang as Chief Operating Officer 2China Nepstar Chain Drugstore Appoints Ms. Rebecca Yingnan Zhang as Chief Operating Officer 3Arena Pharmaceuticals to Present at Piper Jaffray 26th Annual Healthcare Conference 2Arena Pharmaceuticals to Present at Piper Jaffray 26th Annual Healthcare Conference 3
... -- Tongjitang Chinese Medicines Company ("Tongjitang" or the "Company"; ... of its acquisition by Hanmax Investment Limited, a British ... Limited, a company incorporated in Hong Kong ("Fosun"). As ... wholly owned subsidiary of Hanmax and Fosun. Hanmax is ...
... two-year retrospective cohort study presented at the 63rd Annual ... U.S., showed that patients were significantly more likely to ... chronic ischemic heart diseases after an initial diagnosis of ... "These findings suggest a significant association between a ...
Cached Medicine Technology:Tongjitang Chinese Medicines Company Announces Closing of Merger and Intent to Delist from the NYSE 2Tongjitang Chinese Medicines Company Announces Closing of Merger and Intent to Delist from the NYSE 3New Research Links Restless Legs Syndrome (RLS) to Cardiovascular Disease 2New Research Links Restless Legs Syndrome (RLS) to Cardiovascular Disease 3
(Date:11/26/2014)... Kansas (PRWEB) November 26, 2014 ... will showcase expanded capabilities at RSNA 2014 in ... access, manage and share diagnostic images, photos, videos ... to Perceptive’s booth #8107 will learn more about ... newly acquired technologies and partner initiatives – that ...
(Date:11/26/2014)... who enter puberty early are at increased risk for ... linked with a number of factors associated with depression, ... to the researchers. Early puberty was also linked to ... and having friends who were prone to getting into ... an association between early puberty and these factors, it,s ...
(Date:11/26/2014)... of emergency department visits in the United States rose from ... in 2011, according to the U.S. Centers for Disease Control ... were going to ERs with non-urgent medical needs: 96 percent ... hours of arriving at the ER. In 2010, that number ... of patients arrived at the ER after normal business hours ...
(Date:11/26/2014)... HealthDay Reporter TUESDAY, Nov. 25, 2014 (HealthDay ... disrupt the makeup of bacteria in the digestive system, potentially ... new study suggests. The research doesn,t confirm that ... and study authors aren,t recommending that anyone stop taking the ... used at the lowest dose that provides adequate relief of ...
(Date:11/24/2014)... From embedded sensors and biometrics to elite training ... take center stage at the FitnessTech Summit , presented ... 2015 International CES® , January 6, 2015 in Las Vegas ... The bond between fitness and technology is stronger than ever ... more about the human body. , “Fitness technology has become ...
Breaking Medicine News(10 mins):Health News:Perceptive Software to Demonstrate New Medical Content Management Features and Capabilities at RSNA 2014 2Health News:Perceptive Software to Demonstrate New Medical Content Management Features and Capabilities at RSNA 2014 3Health News:Early Puberty Linked to Increased Risk of Depression in Teens 2Health News:ER Visits on the Rise, Study Reports 2Health News:Could Popular Heartburn Drugs Upset Your 'Good' Gut Bugs? 2Health News:Could Popular Heartburn Drugs Upset Your 'Good' Gut Bugs? 3Health News:Next Wave Fitness Products Debut at FitnessTech Summit Living in Digital Times at the 2015 International CES 2Health News:Next Wave Fitness Products Debut at FitnessTech Summit Living in Digital Times at the 2015 International CES 3Health News:Next Wave Fitness Products Debut at FitnessTech Summit Living in Digital Times at the 2015 International CES 4
... - Nuvo Research Inc.,(TSX: NRI), a Canadian ... and,development of drug products delivered to and ... drug delivery technologies, and Paladin Labs Inc.,(TSX: ... today,announced modifications to their existing licensing arrangements ...
... Social Security Disability Insurance Should Know Their Income History; Allsup Answers ... ... 8, 2008 -- People who find themselves with a mental or ... the emotional struggle to accept that they no longer can work. ...
... Services® (PPS®), renowned for its award-winning ... an on-demand, interactive case study, Beyond ... for Mid-Face Volumizing, now available on ... explores treatment options for the use ...
... With Only the Best Medical Travel Agencies , ... Vernon Hills, Illinois ... heats up in the U.S., more and more medical tourism agencies (MTAs) ... hospitals should be aware that not all MTAs are created equally. According ...
... Consumer-driven health plans (CDHP) -- hailed since their ... control costs -- are resulting in members forgoing ... problems, according to two newly published studies. , ... out-of-pocket or from a dedicated health-care account before ...
... Research,Center challenged a team of elite climbers to scale ... efforts of researchers to eliminate,cancer as a cause of ... on the Big Expedition for Cancer Research has,recently returned ... the 7,800-foot level of an unclimbed, unnamed peak, as ...
Cached Medicine News:Health News:Nuvo Research and Paladin announce amendments to Pennsaid and Pennsaid Plus agreements 2Health News:Nuvo Research and Paladin announce amendments to Pennsaid and Pennsaid Plus agreements 3Health News:Past Earnings Play Role in Determining SSDI Benefits 2Health News:Past Earnings Play Role in Determining SSDI Benefits 3Health News:Past Earnings Play Role in Determining SSDI Benefits 4Health News:Past Earnings Play Role in Determining SSDI Benefits 5Health News:AestheticEnhance.org Launches CME-Certified Case Study on Mid-Face Volumizing 2Health News:AestheticEnhance.org Launches CME-Certified Case Study on Mid-Face Volumizing 3Health News:An American Appeal to Overseas Hospitals 2Health News:Members of consumer-driven health plans choosing less care 2Health News:Inaugural Big Expedition for Cancer Research Encounters Mountain As Challenging As Finding a Cure for Cancer 2Health News:Inaugural Big Expedition for Cancer Research Encounters Mountain As Challenging As Finding a Cure for Cancer 3Health News:Inaugural Big Expedition for Cancer Research Encounters Mountain As Challenging As Finding a Cure for Cancer 4
The new CR6-45NM non-mydriatic retinal camera is an ideal diagnostic tool for ophthalmologists, optometrists and other medical professionals, especially when it comes to detecting and monitoring diab...
An ideal choice for film photography. The new TRC-50FXC provides 35mm color and Polaroid capability....
Digital imaging for optical screening: Diabetes, glaucoma macular degeneration, and other retinal disease....
All welded construction for strength and durability. Choice of stainless steel or chrome plated models....
Medicine Products: